345 related articles for article (PubMed ID: 12009916)
1. The A167Y mutation converts the herpes simplex virus type 1 thymidine kinase into a guanosine analogue kinase.
Balzarini J; Liekens S; Esnouf R; De Clercq E
Biochemistry; 2002 May; 41(20):6517-24. PubMed ID: 12009916
[TBL] [Abstract][Full Text] [Related]
2. Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine-167 to tyrosine.
Degrève B; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2000 Dec; 58(6):1326-32. PubMed ID: 11093770
[TBL] [Abstract][Full Text] [Related]
3. Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation.
Balzarini J; Liekens S; Solaroli N; El Omari K; Stammers DK; Karlsson A
J Biol Chem; 2006 Jul; 281(28):19273-9. PubMed ID: 16702226
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs.
Neyts J; De Clercq E
Antimicrob Agents Chemother; 1999 Dec; 43(12):2885-92. PubMed ID: 10582877
[TBL] [Abstract][Full Text] [Related]
5. Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase.
Degrève B; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2001 Feb; 59(2):285-93. PubMed ID: 11160865
[TBL] [Abstract][Full Text] [Related]
6. Conservative mutations of glutamine-125 in herpes simplex virus type 1 thymidine kinase result in a ganciclovir kinase with minimal deoxypyrimidine kinase activities.
Hinds TA; Compadre C; Hurlburt BK; Drake RR
Biochemistry; 2000 Apr; 39(14):4105-11. PubMed ID: 10747801
[TBL] [Abstract][Full Text] [Related]
7. A new acycloguanosine-specific supermutant of herpes simplex virus type 1 thymidine kinase suitable for PET imaging and suicide gene therapy for potential use in patients treated with pyrimidine-based cytotoxic drugs.
Likar Y; Dobrenkov K; Olszewska M; Vider E; Shenker L; Cai S; Pillarsetty N; Hricak H; Ponomarev V
J Nucl Med; 2008 May; 49(5):713-20. PubMed ID: 18413388
[TBL] [Abstract][Full Text] [Related]
8. Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1.
Bae PK; Kim JH; Kim HS; Chung IK; Paik SG; Lee CK
Antiviral Res; 2006 Jul; 70(3):93-104. PubMed ID: 16546268
[TBL] [Abstract][Full Text] [Related]
9. Substrate specificity and molecular modelling of the feline herpesvirus-1 thymidine kinase.
Hussein IT; Miguel RN; Tiley LS; Field HJ
Arch Virol; 2008; 153(3):495-505. PubMed ID: 18196203
[TBL] [Abstract][Full Text] [Related]
10. Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity.
Burrel S; Bonnafous P; Hubacek P; Agut H; Boutolleau D
Antiviral Res; 2012 Dec; 96(3):386-90. PubMed ID: 23041200
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, 18F-radiolabelling and biological evaluations of C-6 alkylated pyrimidine nucleoside analogues.
Raić-Malić S; Johayem A; Ametamey SM; Batinac S; De Clercq E; Folkers G; Scapozza L
Nucleosides Nucleotides Nucleic Acids; 2004; 23(11):1707-21. PubMed ID: 15598073
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
Focher F; Lossani A; Verri A; Spadari S; Maioli A; Gambino JJ; Wright GE; Eberle R; Black DH; Medveczky P; Medveczky M; Shugar D
Antimicrob Agents Chemother; 2007 Jun; 51(6):2028-34. PubMed ID: 17438061
[TBL] [Abstract][Full Text] [Related]
13. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.
Kokoris MS; Black ME
Protein Sci; 2002 Sep; 11(9):2267-72. PubMed ID: 12192082
[TBL] [Abstract][Full Text] [Related]
14. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir.
Sarisky RT; Quail MR; Clark PE; Nguyen TT; Halsey WS; Wittrock RJ; O'Leary Bartus J; Van Horn MM; Sathe GM; Van Horn S; Kelly MD; Bacon TH; Leary JJ
J Virol; 2001 Feb; 75(4):1761-9. PubMed ID: 11160674
[TBL] [Abstract][Full Text] [Related]
15. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
Meng Q; Hagemeier SR; Fingeroth JD; Gershburg E; Pagano JS; Kenney SC
J Virol; 2010 May; 84(9):4534-42. PubMed ID: 20181711
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of cytostatic action of novel 5-(thien-2-yl)- and 5-(furan-2-yl)-substituted pyrimidine nucleoside analogues against tumor cells transfected by the thymidine kinase gene of herpes simplex virus.
Bohman C; Balzarini J; Wigerinck P; Van Aerschot A; Herdewijn P; De Clercq E
J Biol Chem; 1994 Mar; 269(11):8036-43. PubMed ID: 8132526
[TBL] [Abstract][Full Text] [Related]
17. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase.
Gustafson EA; Chillemi AC; Sage DR; Fingeroth JD
Antimicrob Agents Chemother; 1998 Nov; 42(11):2923-31. PubMed ID: 9797227
[TBL] [Abstract][Full Text] [Related]
18. Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain.
Saijo M; Suzutani T; De Clercq E; Niikura M; Maeda A; Morikawa S; Kurane I
Antiviral Res; 2002 Dec; 56(3):253-62. PubMed ID: 12406508
[TBL] [Abstract][Full Text] [Related]
19. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells.
Balzarini J; Bohman C; Walker RT; de Clercq E
Mol Pharmacol; 1994 Jun; 45(6):1253-8. PubMed ID: 8022417
[TBL] [Abstract][Full Text] [Related]
20. Mutation of herpesvirus thymidine kinase to generate ganciclovir-specific kinases for use in cancer gene therapies.
Mercer KE; Ahn CE; Coke A; Compadre CM; Drake RR
Protein Eng; 2002 Nov; 15(11):903-11. PubMed ID: 12538910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
